Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Nuclear Receptor ROR Gamma Treatment Pipeline Review H2 2016

Wednesday, October 26, 2016 23:05
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Pipeline Review, H2 2016’, provides in depth analysis on Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted pipeline therapeutics.

Request a sample report @ https://www.wiseguyreports.com/sample-request/711801-nuclear-receptor-ror-gamma-review-h2-2016

The report provides comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) 
- The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Complete report details @ https://www.wiseguyreports.com/reports/711801-nuclear-receptor-ror-gamma-review-h2-2016      

Key points in table of content

Table of Contents 2 
List of Tables 7 
List of Figures 8 
Introduction 9 
Report Coverage 9 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Overview 10 
Therapeutics Development 11 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Products under Development by Stage of Development 11 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Products under Development by Therapy Area 12 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Products under Development by Indication 13 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Pipeline Products Glance 15 
Late Stage Products 15 
Early Stage Products 16 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Products under Development by Companies 17 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Products under Development by Universities/Institutes 22 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Therapeutics Assessment 24 
Assessment by Monotherapy/Combination Products 24 
Assessment by Mechanism of Action 25 
Assessment by Route of Administration 27 
Assessment by Molecule Type 29 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Companies Involved in Therapeutics Development 30 
AbbVie Inc 30 
Advinus Therapeutics Ltd 31 
Arrien Pharmaceuticals, LLC 32 
Aurigene Discovery Technologies Limited 33 
Beijing Hanmi Pharmaceutical Co., Ltd. 34 
Biogen Inc 35 
Brickell Biotech, Inc. 36 
Bristol-Myers Squibb Company 37 
Celgene Corporation 38 
Eli Lilly and Company 39 
Genentech, Inc. 40 
Genfit SA 41 
GlaxoSmithKline Plc 42 
Japan Tobacco Inc. 43 
Lead Pharma Holding B.V. 44 
Nuevolution AB 45 
Pfizer Inc. 46 
Phenex Pharmaceuticals AG 47 
Reata Pharmaceuticals, Inc. 48 
Takeda Pharmaceutical Company Limited 49 
Teijin Pharma Limited 50 
Visionary Pharmaceuticals, Inc. 51 
Vitae Pharmaceuticals, Inc. 52 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Drug Profiles 53 
ABBV-553 – Drug Profile 53 
Product Description 53 
Mechanism Of Action 53 
R&D Progress 53 
ARN-6039 – Drug Profile 54 
Product Description 54 
Mechanism Of Action 54 
R&D Progress 54 
BBI-6000 – Drug Profile 55 
Product Description 55 
Mechanism Of Action 55 
R&D Progress 55 
Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis – Drug Profile 57 
Product Description 57 
Mechanism Of Action 57 
R&D Progress 57 
GSK-2981278 – Drug Profile 58 
Product Description 58 
Mechanism Of Action 58 
R&D Progress 58 
INV-17 – Drug Profile 59 
Product Description 59 
Mechanism Of Action 59 
R&D Progress 59 
JTE-451 – Drug Profile 60 
Product Description 60 
Mechanism Of Action 60 
R&D Progress 60 
Small Molecule to Agonize ROR-Gamma for Inflammation, Respiratory and Oncology – Drug Profile 61 
Product Description 61 
Mechanism Of Action 61 
R&D Progress 61 
Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis – Drug Profile 62 
Product Description 62 
Mechanism Of Action 62 
R&D Progress 62 
Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis – Drug Profile 63 
Product Description 63 
Mechanism Of Action 63 
R&D Progress 63 
Small Molecule to Target ROR Gamma for Autoimmune Disorders – Drug Profile 64 
Product Description 64 
Mechanism Of Action 64 
R&D Progress 64 
Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Inflammatory Bowel Disease – Drug Profile 65 
Product Description 65 
Mechanism Of Action 65 
R&D Progress 65 
Small Molecules to Agonize ROR gamma for Breast Cancer – Drug Profile 66 
Product Description 66 
Mechanism Of Action 66 
R&D Progress 66 
Small Molecules to Agonize ROR-Gamma for Autoimmune Disease – Drug Profile 68 
Product Description 68 
Mechanism Of Action 68 
R&D Progress 68 
Small Molecules to Agonize ROR-Gamma for Oncology – Drug Profile 69 
Product Description 69 
Mechanism Of Action 69 
R&D Progress 69 
Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders – Drug Profile 70 
Product Description 70 
Mechanism Of Action 70 
R&D Progress 70 
Small Molecules to Antagonize ROR-Gamma T for Rheumatoid Arthritis and Psoriasis – Drug Profile 71 
Product Description 71 
Mechanism Of Action 71 
R&D Progress 71 
Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation – Drug Profile 72 
Product Description 72 
Mechanism Of Action 72 
R&D Progress 72 
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis – Drug Profile 73 
Product Description 73 
Mechanism Of Action 73 
R&D Progress 73 
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis – Drug Profile 74 
Product Description 74 
Mechanism Of Action 74 
R&D Progress 74 
Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases – Drug Profile 75 
Product Description 75 
Mechanism Of Action 75 
R&D Progress 75 
Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis – Drug Profile 76 
Product Description 76 
Mechanism Of Action 76 
R&D Progress 76 
Small Molecules to Inhibit ROR-Gamma for Inflammation – Drug Profile 77 
Product Description 77 
Mechanism Of Action 77 
R&D Progress 77 
Small Molecules to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation – Drug Profile 78 
Product Description 78 
Mechanism Of Action 78 
R&D Progress 78 
Small Molecules to Target ROR gamma for Autoimmune Diseases – Drug Profile 79 
Product Description 79 
Mechanism Of Action 79 
R&D Progress 79 
SR-1001 – Drug Profile 80 
Product Description 80 
Mechanism Of Action 80 
R&D Progress 80 
SR-2211 – Drug Profile 81 
Product Description 81 
Mechanism Of Action 81 
R&D Progress 81 
TAK-828 – Drug Profile 82 
Product Description 82 
Mechanism Of Action 82 
R&D Progress 82 
TGFTX-1 – Drug Profile 83 
Product Description 83 
Mechanism Of Action 83 
R&D Progress 83 
TMP-778 – Drug Profile 84 
Product Description 84 
Mechanism Of Action 84 
R&D Progress 84 
VPR-66 – Drug Profile 85 
Product Description 85 
Mechanism Of Action 85 
R&D Progress 85 
VTP-43742 – Drug Profile 86 
Product Description 86 
Mechanism Of Action 86 
R&D Progress 86 
VTP-45489 – Drug Profile 88 
Product Description 88 
Mechanism Of Action 88 
R&D Progress 88 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Dormant Projects 89 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Discontinued Products 90 
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Featured News & Press Releases 91 
Jun 06, 2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer 91 
Jun 03, 2016: Arrien Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a New Agent for Treatment of Multiple Sclerosis 91 
May 09, 2016: Arrien Pharmaceuticals to Initiate the Phase I Clinical trials of Autoimmune Drug 92 
Apr 29, 2016: Arrien Pharmaceuticals Announces FDA Accepts IND Application For ARN-6039 92 
Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis 93 
Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742 93 
Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting 94 
Nov 02, 2015: Lead Pharma Achieves first Milestone for Developmen t of Autoimmune Diseases Treatments in Research Collabor ation with Sanofi 95 
Sep 29, 2015: Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients 96 
Sep 08, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders 96 
Aug 10, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders 97 
Aug 05, 2015: Aurigene to Present its RORg Inverse Agonist Program at World Congress on Inflammation, 2015 97 
Jun 29, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders 98 
Apr 16, 2015: Vitae Pharmaceuticals to Present at Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases 98 
Mar 17, 2015: New Compound Prevents Type 1 Diabetes in Animal Models—Before It Begins 99 
Appendix 100 
Methodology 100 
Coverage 100 
Secondary Research 100 
Primary Research 100 
Expert Panel Validation 100 
Contact Us 100 
Disclaimer 101

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=711801

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.